1-17 of 17
Robert Z. Orlowski
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma

Krina K. Patel, Jatin J. Shah, Lei Feng, Hans C. Lee, Elisabet M. Manasanch, Jasper Olsem, Ashley Morphey, Xiao Jiao Huo, Sheeba K. Thomas, Qaiser Bashir, Muzaffar H. Qazilbash, Donna M. Weber, Robert Z. Orlowski
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1277–1284.
https://doi.org/10.1158/1078-0432.CCR-21-3420
Published: 01 April 2022
View article titled, Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma
Open the PDF for Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma in another window
Includes: Supplementary data
Journal Articles

Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma

Sikander Ailawadhi, Rachael Sexton, Suzanne Lentzsch, Muneer H. Abidi, Peter M. Voorhees, Adam D. Cohen, Eric M. Rohren, Stephen Heitner, Kevin Kelly, Niklas J. Mackler, David M. Baer, Antje Hoering, Brian Durie, Robert Z. Orlowski
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15): 3969–3978.
https://doi.org/10.1158/1078-0432.CCR-19-1997
Published: 03 August 2020
View article titled, Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma
Open the PDF for Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma in another window
Journal Articles

Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis

Neeraj Saini, Junsheng Ma, Denái R. Milton, Romil Patel, Ankur Varma, Qaiser Bashir, Ruby Delgado, Akash Mukherjee, Gabriela Rondon, Uday R. Popat, Chitra M. Hosing, Yago Nieto, Partow Kebriaei, Amin M. Alousi, Sairah Ahmed, Guilin Tang, Rohtesh Mehta, Samer Srour, Issa F. Khouri, Swaminathan Iyer, Donna M. Weber, Sheeba K. Thomas, Hans C. Lee, Elisabet E. Manasanch, Krina K. Patel, Robert Z. Orlowski, Richard E. Champlin, Muzaffar H. Qazilbash
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6781–6787.
https://doi.org/10.1158/1078-0432.CCR-19-0706
Published: 15 November 2019
View article titled, Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis
Open the PDF for Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis in another window
Includes: Supplementary data
Journal Articles

Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191

Haiwen Ni, Fazal Shirazi, Veerabhadran Baladandayuthapani, Heather Lin, Isere Kuiatse, Hua Wang, Richard J. Jones, Zuzana Berkova, Yasumichi Hitoshi, Stephen M. Ansell, Steven P. Treon, Sheeba K. Thomas, Hans C. Lee, Zhiqiang Wang, R. Eric Davis, Robert Z. Orlowski
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6408–6420.
https://doi.org/10.1158/1078-0432.CCR-17-3265
Published: 13 December 2018
View article titled, Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Open the PDF for Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191 in another window
Includes: Supplementary data
Journal Articles

Integration of Novel Agents into the Care of Patients with Multiple Myeloma

Robert Z. Orlowski, Sagar Lonial
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (22): 5443–5452.
https://doi.org/10.1158/1078-0432.CCR-16-0861
Published: 14 November 2016
View article titled, Integration of Novel Agents into the Care of Patients with Multiple Myeloma
Open the PDF for Integration of Novel Agents into the Care of Patients with Multiple Myeloma in another window
Journal Articles

Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression

Richard J. Jones, Tawin Iempridee, Xiaobin Wang, Hans C. Lee, Janet E. Mertz, Shannon C. Kenney, Heather C. Lin, Veerabhadran Baladandayuthapani, Christopher W. Dawson, Jatin J. Shah, Donna M. Weber, Robert Z. Orlowski
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (19): 4901–4912.
https://doi.org/10.1158/1078-0432.CCR-15-2242
Published: 02 October 2016
View article titled, Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression
Open the PDF for Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

Jatin J. Shah, Andrzej J. Jakubowiak, Owen A. O'Connor, Robert Z. Orlowski, R. Donald Harvey, Mitchell R. Smith, Daniel Lebovic, Catherine Diefenbach, Kevin Kelly, Zhaowei Hua, Allison J. Berger, George Mulligan, Hélène M. Faessel, Stephen Tirrell, Bruce J. Dezube, Sagar Lonial
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (1): 34–43.
https://doi.org/10.1158/1078-0432.CCR-15-1237
Published: 03 January 2016
View article titled, Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
Open the PDF for Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma in another window
Includes: Supplementary data
Journal Articles

Abstract A45: Osteoblastic niche supports the growth of quiescent multiple myeloma cells.

Zheng Chen, Robert Z. Orlowski, Michael Wang, Larry Kwak, Nami McCarty
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17_Supplement): A45.
https://doi.org/10.1158/1557-3265.HEMMAL14-A45
Published: 19 August 2015
View article titled, Abstract A45: Osteoblastic niche supports the growth of quiescent multiple myeloma cells.
Journal Articles

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia

Isere Kuiatse, Veerabhadran Baladandayuthapani, Heather Y. Lin, Sheeba K. Thomas, Chad C. Bjorklund, Donna M. Weber, Michael Wang, Jatin J. Shah, Xing-Ding Zhang, Richard J. Jones, Stephen M. Ansell, Guang Yang, Steven P. Treon, Robert Z. Orlowski
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (11): 2538–2545.
https://doi.org/10.1158/1078-0432.CCR-14-1462
Published: 31 May 2015
View article titled, Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia
Open the PDF for Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia in another window
Includes: Supplementary data
Journal Articles

Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer In Vitro and In Vivo via Exacerbating Unfolded Protein Responses

Kathleen Coughlin, Ravi Anchoori, Yoshie Iizuka, Joyce Meints, Lauren MacNeill, Rachel Isaksson Vogel, Robert Z. Orlowski, Michael K. Lee, Richard B.S. Roden, Martina Bazzaro
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (12): 3174–3186.
https://doi.org/10.1158/1078-0432.CCR-13-2658
Published: 12 June 2014
View article titled, Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer <em>In Vitro</em> and <em>In Vivo</em> via Exacerbating Unfolded Protein Responses
Open the PDF for Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer <em>In Vitro</em> and <em>In Vivo</em> via Exacerbating Unfolded Protein Responses in another window
Includes: Supplementary data
Journal Articles

Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation

Xin Shelley Wang, Qiuling Shi, Nina D. Shah, Cobi J. Heijnen, Evan N. Cohen, James M. Reuben, Robert Z. Orlowski, Muzaffar H. Qazilbash, Valen E. Johnson, Loretta A. Williams, Tito R. Mendoza, Charles S. Cleeland
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (5): 1366–1374.
https://doi.org/10.1158/1078-0432.CCR-13-2442
Published: 02 March 2014
View article titled, Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation
Open the PDF for Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation in another window
Journal Articles

Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma

Ruben Niesvizky, Thomas G. Martin, III, William I. Bensinger, Melissa Alsina, David S. Siegel, Lori A. Kunkel, Alvin F. Wong, Susan Lee, Robert Z. Orlowski, Michael Wang
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (8): 2248–2256.
https://doi.org/10.1158/1078-0432.CCR-12-3352
Published: 15 April 2013
View article titled, Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma
Open the PDF for Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma in another window
Journal Articles

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

Owen A. O'Connor, A. Keith Stewart, Marcy Vallone, Christopher J. Molineaux, Lori A. Kunkel, John F. Gerecitano, Robert Z. Orlowski
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (22): 7085–7091.
https://doi.org/10.1158/1078-0432.CCR-09-0822
Published: 11 November 2009
View article titled, A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
Open the PDF for A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies in another window
Journal Articles

Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage–Independent p53 Phosphorylation in Mantle Cell Lymphoma

Richard J. Jones, Qing Chen, Peter M. Voorhees, Ken H. Young, Nathalie Bruey-Sedano, Dajun Yang, Robert Z. Orlowski
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (17): 5416–5425.
https://doi.org/10.1158/1078-0432.CCR-08-0150
Published: 02 September 2008
View article titled, Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage–Independent p53 Phosphorylation in Mantle Cell Lymphoma
Open the PDF for Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage–Independent p53 Phosphorylation in Mantle Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

Robert Z. Orlowski, Deborah J. Kuhn
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (6): 1649–1657.
https://doi.org/10.1158/1078-0432.CCR-07-2218
Published: 17 March 2008
View article titled, Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
Open the PDF for Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade in another window
Journal Articles

Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma

Peter M. Voorhees, Qing Chen, Deborah J. Kuhn, George W. Small, Sally A. Hunsucker, John S. Strader, Robert E. Corringham, Mohamed H. Zaki, Jeffrey A. Nemeth, Robert Z. Orlowski
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (21): 6469–6478.
https://doi.org/10.1158/1078-0432.CCR-07-1293
Published: 01 November 2007
View article titled, Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma
Open the PDF for Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

The Proteasome as a Target for Cancer Therapy

Peter M. Voorhees, E. Claire Dees, Bert O’Neil, Robert Z. Orlowski
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (17): 6316–6325.
Published: 24 December 2003
View article titled, The Proteasome as a Target for Cancer Therapy
Open the PDF for The Proteasome as a Target for Cancer Therapy in another window